Stockreport

Vir Biotechnology Announces Encouraging Safety and Efficacy Data in Ongoing Dose Escalation Trials for Dual Masked T-Cell Engagers VIR-5818 in Solid Tumors and VIR-5500 in mCRPC

Vir Biotechnology, Inc.  (VIR) 
PDF – Compelling early clinical response signals for VIR-5818 and VIR-5500 in heavily pretreated patients with various solid tumors? VIR-5818: In patients receiving doses =4 [Read more]